Core Viewpoint - The company, Haiprui, is a leading multinational pharmaceutical enterprise with a focus on the heparin industry chain, biopharmaceutical CDMO, and innovative drug development, benefiting from the depreciation of the RMB and a significant overseas revenue share [2][3]. Company Overview - Haiprui was established in 1998 in Shenzhen and has both A and H share financing platforms [2]. - The main business segments include heparin sodium raw materials, downstream low molecular weight heparin products, and CDMO services for biopharmaceuticals [7]. - As of June 30, 2025, Haiprui reported a revenue of 2.817 billion yuan, a year-on-year decrease of 0.71%, and a net profit of 422 million yuan, down 36.44% year-on-year [7]. Financial Performance - The company’s overseas revenue accounted for 93.04% of total revenue, benefiting from the depreciation of the RMB [3]. - The revenue composition includes 63.06% from formulations, 18.59% from CDMO, 16.05% from heparin sodium and low molecular weight heparin raw materials, and 2.30% from other sources [7]. - Cumulative cash dividends since the A-share listing amount to 4.21 billion yuan, with 514 million yuan distributed over the past three years [8]. Market Activity - On September 22, Haiprui's stock price fell by 0.81%, with a trading volume of 45.2628 million yuan and a market capitalization of 18.062 billion yuan [1]. - The stock has seen a net outflow of 3.1095 million yuan from major funds today, indicating a reduction in holdings over the past three days [4][5]. Technical Analysis - The average trading cost of the stock is 11.56 yuan, with the current price approaching a resistance level of 12.33 yuan, suggesting potential for a price correction if this level is not surpassed [6].

Core Viewpoint - Haiprime is a leading multinational pharmaceutical company with a focus on heparin, biopharmaceuticals, and innovative drugs, benefiting from the depreciation of the RMB and its strong overseas revenue [2][3]. Company Overview - Established in 1998 in Shenzhen, Haiprime operates with A+H dual financing platforms and is dedicated to providing high-quality and effective medications globally [2]. - The company’s main business segments include heparin products (20.25%), CDMO services (19.58%), and formulations (56.55%) [7]. Financial Performance - For the period from January to March 2025, Haiprime reported a revenue of 1.394 billion yuan, representing a year-on-year growth of 1.53%, and a net profit attributable to shareholders of 157 million yuan, up by 1.00% [7]. - As of March 31, 2025, the company had a total market capitalization of 19.486 billion yuan [1]. Shareholder Information - As of March 31, 2025, Haiprime had 28,400 shareholders, an increase of 6.00% from the previous period [7]. - The company has distributed a total of 4.21 billion yuan in dividends since its A-share listing, with 514 million yuan distributed over the last three years [8]. Market Dynamics - Haiprime's overseas revenue accounted for 93.04% of its total revenue, benefiting from the depreciation of the RMB [3]. - The company is positioned within the pharmaceutical and biotechnology sectors, focusing on vaccines, innovative drugs, and raw materials [7]. Technical Analysis - The average trading cost of Haiprime's shares is 11.40 yuan, with the current stock price near a support level of 12.91 yuan [6].

Core Viewpoint - The article discusses the performance and business operations of Haiprui, a leading multinational pharmaceutical company, highlighting its revenue structure and market dynamics, particularly in relation to the depreciation of the Chinese yuan and its impact on overseas revenue [2][3]. Company Overview - Haiprui was established in 1998 in Shenzhen and operates with A+H dual financing platforms, focusing on the heparin industry chain, biopharmaceutical CDMO, and innovative drug development [2]. - The company’s main business revenue composition includes: formulations (56.55%), heparin sodium and low molecular weight heparin raw materials (20.25%), CDMO (19.58%), and others (3.63%) [7]. - As of March 31, 2025, Haiprui reported a revenue of 1.394 billion yuan, a year-on-year increase of 1.53%, and a net profit attributable to shareholders of 157 million yuan, up 1.00% year-on-year [7]. Financial Performance - Haiprui's overseas revenue accounts for 93.04% of its total revenue, benefiting from the depreciation of the yuan [3]. - The company has distributed a total of 4.21 billion yuan in dividends since its A-share listing, with 514 million yuan distributed over the past three years [8]. Market Dynamics - The stock experienced a decline of 1.40% on July 31, with a trading volume of 152 million yuan and a turnover rate of 0.91%, resulting in a total market capitalization of 19.647 billion yuan [1]. - The stock's average trading cost is 11.28 yuan, with recent buying activity observed, although the buying pressure is not strong [6]. - The stock is currently trading between resistance at 13.88 yuan and support at 12.41 yuan, indicating potential for range trading [6]. Institutional Holdings - As of March 31, 2025, Haiprui's top ten circulating shareholders include Hong Kong Central Clearing Limited and Innovation Drug, with increases in their holdings compared to the previous period [8].